(Center for Genomic Regulation) The European Research Council today announced the results of the 2018 ERC Synergy Grants Call. A project, the [email protected], of four research groups from the Centro Nacional de An á lisis Gen ó mico of the Centre for Genomic Regulation, and the Institut d’Investigacions Biom è diques August Pi i Sunyer have received this prestigious grant to unravel the genomics and epigenomics of chronic lymphocytic leukemia at unprecedented resolution using single-cell analysis.

Related Links:

Environmental factors have an impact on the effectiveness of treatments for chronic lymphocytic leukemia: vulnerability, organization of the supply of care and proximity of the patient to health professionals. The disparity of care was assessed; vulnerability by the European index of deprivation, the provision of care by values of localized potential accessibility to general practitioners, nurses and pharmacists and hospital supply by the density of hematologists and time access to the center. The data, extracted from the public databases for each grouped island for statistical information, were cross-ref…

Source: Bulletin du CancerCategory: Cancer & Oncology Authors: Tags: Bull Cancer Source Type: research

In this report, 3 transbronchial biopsies showed viral inclusions on histologic examination and were evaluated for anti-SV40 large T antigen (SV40 T Ag) by immunohistochemistry (IHC), in situ hybridization, and viral genome sequencing by polymerase chain reaction. Patients 1 and 2 were immunosuppressed lung transplant recipients. Patient 1 presented with diffuse pruritic rash and respiratory failure, and patient 2 with PyV viremia. Patient 3 had chronic lymphocytic leukemia/small lymphocytic lymphoma and presented with cough and shortness of breath. Histologic examination of all 3 lung biopsies were similar and revealed pr…

Source: Pathology Case ReviewsCategory: Pathology Tags: Call for Papers 2017 Source Type: research

ConclusionsThe modest changes in venetoclax exposures when given with azithromycin indicate that no dose adjustment would be needed when venetoclax is coadministered with azithromycin or other drugs with P-gp inhibitory potential. Azithromycin represents an alternative to other antimicrobial agents with higher potential to alter venetoclax pharmacokinetics such as clarithromycin, erythromycin, and ciprofloxacin.FundingAbbVie in collaboration with Genentech/Roche.

Source: Advances in TherapyCategory: Drugs & Pharmacology Source Type: research

CONCLUSIONS: This specific IgM increase in patients underpins the key role of tissue-based engagement with antigen in CLL, confirms the inhibitory action of ibrutinib, and reveals dynamic adaptability of CLL cells to precision monotherapy.
PMID: 30373751 [PubMed – as supplied by publisher]

Source: Clinical Cancer ResearchCategory: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research

Microenvironmental signaling is pivotal to chronic lymphocytic leukemia (CLL) pathology; therefore understanding how to investigate this pathway by both protein and chemical methods is crucial if we are to investigate and correlate biological changes with therapeutic responses in patients. Herein, we describe the use of western blotting also referred to as immunoblotting as a method that can semiquantitatively evaluate changes in protein expression following receptor engagement; this includes B cell receptor (BCR) signaling following stimulation with anti-IgM (Blunt et al. Clin Cancer Res 23(9):2313-2324,…

Source: Mol Biol CellCategory: Molecular Biology Authors: Tags: Methods Mol Biol Source Type: research

This article summarizes the milestones in the deve lopment of moxetumomab pasudotox leading to this first approval for the treatment of adults with relapsed or refractory hairy cell leukaemia who received at least two prior systemic therapies, including treatment with a purine nucleoside analogue. Development of moxetumomab pasudotox for non-Hodgkin ’s lymphoma, chronic lymphocytic leukaemia and precursor cell lymphoblastic leukaemia/lymphoma was discontinued.

Source: DrugsCategory: Drugs & Pharmacology Source Type: research

Genes, Chromosomes and Cancer,Volume 0, Issue ja, -Not available-.

Source: Genes, Chromosomes and CancerCategory: Cancer & Oncology Authors: Source Type: research

Cancer, EarlyView.

Source: CancerCategory: Cancer & Oncology Authors: Source Type: research

CONCLUSIONS: Cerdulatinib potently and selectively inhibited SYK/JAK signaling at tolerated exposures in patients with relapsed/refractory B-cell malignancies. The extent of target inhibition in whole-blood assays and suppression of inflammation correlated with tumor response. (ClinicalTrials.gov ID:NCT01994382).
PMID: 30333224 [PubMed – as supplied by publisher]

Source: Clinical Cancer ResearchCategory: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research

Publication date: Available online 16 October 2018Source: Cancer GeneticsAuthor(s): Kathy Chun, Gail D. Wenger, Alka Chaubey, D.P. Dash, Rashmi Kanagal-Shamanna, Sibel Kanturci, Ravindra Kolhe, Daniel L. Van Dyke, Lu Wang, Daynna J. Wolff, Patricia M. MironAbstractThe prognostic role of cytogenetic analysis is well-established in B-cell chronic lymphocytic leukemia (CLL). Approximately 80% of patients have a cytogenetic aberration. Interphase FISH panels have been the gold standard for cytogenetic evaluation, but conventional cytogenetics allows detection of additional abnormalities, including translocations, complex karyo…

Source: Cancer GeneticsCategory: Cancer & Oncology Source Type: research


Source link


Please enter your comment!
Please enter your name here